HC Wainwright Has Bearish Forecast for NovoCure Q1 Earnings

NovoCure Limited (NASDAQ:NVCR) – Equities researchers at HC Wainwright cut their Q1 2026 earnings per share (EPS) estimates for NovoCure in a report released on Thursday, February 5th. HC Wainwright analyst E. Bodnar now forecasts that the medical equipment provider will post earnings of ($0.50) per share for the quarter, down from their prior forecast of ($0.34). HC Wainwright currently has a “Buy” rating and a $39.00 target price on the stock. The consensus estimate for NovoCure’s current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for NovoCure’s Q2 2026 earnings at ($0.32) EPS, FY2026 earnings at ($1.62) EPS and FY2028 earnings at ($0.35) EPS.

A number of other equities analysts also recently issued reports on NVCR. JPMorgan Chase & Co. cut their price target on NovoCure from $25.00 to $23.00 and set a “neutral” rating for the company in a research note on Monday, October 27th. Evercore set a $20.00 target price on NovoCure in a research report on Monday, January 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of NovoCure in a research report on Thursday, January 22nd. Finally, Wedbush reaffirmed a “neutral” rating and set a $18.00 price objective on shares of NovoCure in a report on Thursday, January 15th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $25.50.

NovoCure Stock Up 0.5%

NVCR stock opened at $10.14 on Monday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.55 and a quick ratio of 1.50. NovoCure has a fifty-two week low of $9.82 and a fifty-two week high of $23.18. The stock has a market capitalization of $1.14 billion, a price-to-earnings ratio of -6.30 and a beta of 0.73. The business’s fifty day moving average price is $12.95 and its two-hundred day moving average price is $12.64.

Institutional Trading of NovoCure

Several hedge funds and other institutional investors have recently modified their holdings of the business. AQR Capital Management LLC boosted its holdings in shares of NovoCure by 56.7% in the first quarter. AQR Capital Management LLC now owns 28,728 shares of the medical equipment provider’s stock worth $512,000 after acquiring an additional 10,394 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of NovoCure by 3.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,992 shares of the medical equipment provider’s stock worth $1,336,000 after buying an additional 2,502 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of NovoCure by 5.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 993,670 shares of the medical equipment provider’s stock valued at $17,707,000 after buying an additional 52,180 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of NovoCure during the 1st quarter worth $87,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of NovoCure by 17.1% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,307 shares of the medical equipment provider’s stock worth $77,000 after acquiring an additional 629 shares during the last quarter. Institutional investors own 84.61% of the company’s stock.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.